Postreperfusion myocardial technetium-99m-sestamibi defect corresponds to area at risk: experimental results from an ischemia-reperfusion porcine model

Runa Hyldgaard Poulsen, Hans Erik Bøtker, Michael Rehling

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Abstract

Technetium-99m-sestamibi (MIBI) is the most frequently used myocardial perfusion tracer in patients with ischemic heart disease. In patients with acute ST-elevation myocardial infarction, we previously found that the defect in myocardial MIBI uptake was the same in patients injected with MIBI before primary angioplasty and in patients injected immediately after successful treatment. Thus, reperfusion may not be followed by increased uptake of MIBI. Instead, the MIBI defect after reperfusion may reflect the area at risk (AAR) defined by MIBI injected before treatment. We intended to investigate whether myocardial imaging with MIBI administered after reperfusion reflects myocardial perfusion or rather the ischemic AAR.
Original languageEnglish
JournalNuclear Medicine and Biology
Volume38
Issue6
Pages (from-to)819-25
Number of pages7
ISSN0969-8051
DOIs
Publication statusPublished - 2011

Keywords

  • Animals
  • Artifacts
  • Biological Transport
  • Disease Models, Animal
  • Female
  • Microspheres
  • Myocardial Perfusion Imaging
  • Reperfusion
  • Reperfusion Injury
  • Reproducibility of Results
  • Risk
  • Swine
  • Technetium Tc 99m Sestamibi

Fingerprint

Dive into the research topics of 'Postreperfusion myocardial technetium-99m-sestamibi defect corresponds to area at risk: experimental results from an ischemia-reperfusion porcine model'. Together they form a unique fingerprint.

Cite this